CO2018006701A2 - Formas polimórficas cristalinas del ácido obeticólico - Google Patents

Formas polimórficas cristalinas del ácido obeticólico

Info

Publication number
CO2018006701A2
CO2018006701A2 CONC2018/0006701A CO2018006701A CO2018006701A2 CO 2018006701 A2 CO2018006701 A2 CO 2018006701A2 CO 2018006701 A CO2018006701 A CO 2018006701A CO 2018006701 A2 CO2018006701 A2 CO 2018006701A2
Authority
CO
Colombia
Prior art keywords
obetolic
polymorphic forms
acid
crystalline polymorphic
obetolic acid
Prior art date
Application number
CONC2018/0006701A
Other languages
English (en)
Inventor
André Steiner
Poulsen Heidi Waenerlund
Emilie Jolibois
Melissa Rewolinski
Ralf Gross
Emma Sharp
Fiona Dubas-Fisher
Alex Eberlin
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018006701(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CO2018006701A2 publication Critical patent/CO2018006701A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN La presente solicitud se refiere a las formas cristalinas A, D, F, G e I del ácido obeticólico. Estas formas cristalinas son útiles en la producción de ácido obeticólico (en particular su purificación), el cual es un fármaco útil para el tratamiento o la prevención de una enfermedad o afección mediada por FXR, enfermedades cardiovasculares o hepatopatía colestásica, y para reducir el colesterol HDL, para reducir los triglicéridos en un mamífero o para inhibir la fibrosis.
CONC2018/0006701A 2015-12-22 2018-06-27 Formas polimórficas cristalinas del ácido obeticólico CO2018006701A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid

Publications (1)

Publication Number Publication Date
CO2018006701A2 true CO2018006701A2 (es) 2018-07-10

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0006701A CO2018006701A2 (es) 2015-12-22 2018-06-27 Formas polimórficas cristalinas del ácido obeticólico

Country Status (15)

Country Link
EP (1) EP3394081A1 (es)
JP (1) JP2018538331A (es)
KR (1) KR20180095070A (es)
CN (1) CN108495858A (es)
AU (1) AU2016375566A1 (es)
BR (1) BR112018012590A2 (es)
CA (1) CA3009149A1 (es)
CL (1) CL2018001720A1 (es)
CO (1) CO2018006701A2 (es)
EA (1) EA201891491A1 (es)
IL (1) IL259998A (es)
MX (1) MX2018007776A (es)
PH (1) PH12018501318A1 (es)
SG (1) SG11201805235XA (es)
WO (1) WO2017111979A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN104781272A (zh) * 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
US20170327531A1 (en) * 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CA2968309A1 (en) * 2014-11-19 2016-05-26 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
EP3221332B1 (en) * 2014-11-19 2019-04-24 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
MX2017006565A (es) * 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).

Also Published As

Publication number Publication date
WO2017111979A1 (en) 2017-06-29
EA201891491A1 (ru) 2018-11-30
BR112018012590A2 (pt) 2018-12-04
JP2018538331A (ja) 2018-12-27
EP3394081A1 (en) 2018-10-31
CA3009149A1 (en) 2017-06-29
MX2018007776A (es) 2018-08-09
SG11201805235XA (en) 2018-07-30
PH12018501318A1 (en) 2019-02-18
CN108495858A (zh) 2018-09-04
CL2018001720A1 (es) 2018-08-10
AU2016375566A1 (en) 2018-07-05
KR20180095070A (ko) 2018-08-24
IL259998A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
CO2018006701A2 (es) Formas polimórficas cristalinas del ácido obeticólico
CO2017001884A2 (es) Polimorfos de selinexor
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2014003455A1 (es) Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
DOP2021000179A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
UY39011A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
CL2018000835A1 (es) Prevención, tratamiento y reversión de la enfermedad usando una cantidad terapeuticamente efectiva de ácidos grasos activados
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
DOP2017000139A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
DK2717692T3 (da) Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme
CR20140342A (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos hepáticos
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
BR112016020260A2 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
CL2017002034A1 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih.
CL2017003133A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
UY36385A (es) Piperidinilpirazolopirimidinonas y utilización de las mismas
FI20155412A (fi) Sokerien suora konversio glykolihapoksi